{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-087740","form_type":"8-K","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2023-11-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.413610+00:00","generated_at":"2026-06-08T00:53:43.430110+00:00","sec_items":["1.01","2.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ABVC and BioLite license CNS drugs to AiBtl for 23M shares plus milestones; gains controlling interest","bullets":["Licensed products (MDD and ADHD) valued at $667M by third-party evaluation.","ABVC and BioLite each receive 23M shares of AIBL (targeted $10/share at IPO) within 30 days.","Milestone payments of $3.5M and royalties of 5% of net sales, up to $100M.","Share issuance gives ABVC controlling interest in AiBtl BioPharma Inc."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-087740","json":"https://secwatch.observer/filing/0001213900-23-087740.json","markdown":"https://secwatch.observer/filing/0001213900-23-087740.md","text":"https://secwatch.observer/filing/0001213900-23-087740.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023087740/0001213900-23-087740-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023087740/ea188562-8k_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T00:53:43.430110+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1504262acb2301ac362aa491f9d48dfec4b818fe","claim":"ABVC BIOPHARMA, INC. entered into a license with AiBtl BioPharma Inc. (\"AIBL\") valued at 23 million shares of AIBL stock ... $3,500,000 and royalties equaling 5% of net sales, up to $100 mi (effective 2023-11-12).","evidence_excerpt":"In November 12, 2023, the Company and one of its subsidiaries, BioLite, Inc. (\"BioLite\") each entered into a multi-year, global licensing agreement with AiBtl BioPharma Inc. (\" AIBL \") for the Company and BioLite’s CNS drugs","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023087740/0001213900-23-087740-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"AiBtl BioPharma Inc. (\"AIBL\")"},{"label":"Value","value":"23 million shares of AIBL stock ... $3,500,000 and royalties equaling 5% of net sales, up to $100 mi"},{"label":"Effective","value":"2023-11-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}